Brief: XORTX Announces Submission Of Orphan Drug Designation Request For XRx-008 Program
01/02/2023 12:21
Feb 1 (Reuters) - XORTX Therapeutics Inc XRTX.V :
* XORTX ANNOUNCES SUBMISSION OF ORPHAN DRUG DESIGNATION
REQUEST
FOR XRX-008 PROGRAM TO TREAT AUTOSOMAL DOMINANT KIDNEY DISEASE
Source text for Eikon: ID:nGNX6TPk1d
Further company coverage: XRTX.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on XORTX Therapeutics
See all newsBrief: Xortx Outlines Anticipated Health Canada Clinical Trial Application For Xrx-026 For Gout
Brief: XORTX Therapeutics Announces Initiation Of Drug And Tablet Manufacturing For XRx-026 Program
Brief: Xortx Announces Termination And Postponement Of Investor Relations Program
Brief: XORTX Announces Director Resignation
Brief: Xortx Announces Us$5 Million Public Offering